Notable Labs

Developing a new class of oncology medicines: Predictive Precision Medicines.

About

Founded

2014

Headquarters

Foster City, California

Industry

Biotech

Company Description

Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment: patient population by patient population, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community.

Quick Links

WebsiteJobs

Funding

Total Raised

$54.8 million

Valuation

Undisclosed

Significant Investors

Builders VC, Eleven Two Capital, First Round Capital, Founders Fund, Fuel Capital, Lightspeed Venture Partners, Upside Partnership, Y Combinator, B Capital Group, LifeForce Capital, Industry Ventures

Company Traction

  • Notable’s predictive precision medicine platform identifies responders with 92% accuracy in a study conducted at Stanford in 2020.
  • As of May 2023, NBL-001, a molecule in Notable’s pipeline, is at phase 1 for acute myeloid leukemia (AML) indication, preclinical for pediatric leukemia indication, and preclinical for solid tumors indication.
  • As of May 2023, Fosciclopirox, a molecule in Notable’s pipeline, is pre-clinical for AML indication.

Leadership Team

  • Joseph Wagner: Chief Scientific Officer at Notable. Former Executive Director at the University of California Drug Discovery Consortium.
  • Connor Warnock: Director of Engineering at Notable. Former Lead Software Engineer at Townsquared.
  • Chris Leonardi: Head of Commercial, Partnerships & Alliances at Notable. Former VP of Business Development and Operations at InTeleLabs.

People also viewed